Home/Filings/4/0001562180-25-001026
4//SEC Filing

Russell Alan J 4

Accession 0001562180-25-001026

CIK 0001710072other

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 4:38 PM ET

Size

14.7 KB

Accession

0001562180-25-001026

Insider Transaction Report

Form 4
Period: 2025-02-05
Russell Alan J
DirectorChief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-05$0.18/sh+8,015$1,44322,878 total
  • Exercise/Conversion

    Common Stock

    2025-02-06$0.18/sh+1,200$21616,063 total
  • Sale

    Common Stock

    2025-02-06$30.13/sh1,200$36,15314,863 total
  • Sale

    Common Stock

    2025-02-05$30.02/sh8,015$240,62314,863 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-02-058,0151,348,765 total
    Exercise: $0.18From: 2021-06-27Exp: 2032-06-27Common Stock (8,015 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-02-061,2001,347,565 total
    Exercise: $0.18From: 2021-06-27Exp: 2032-06-27Common Stock (1,200 underlying)
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
  • [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.0216, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.22, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Edgewise Therapeutics, Inc.

CIK 0001710072

Entity typeother

Related Parties

1
  • filerCIK 0001853529

Filing Metadata

Form type
4
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:38 PM ET
Size
14.7 KB